Abstract: Multi-user portable electronic devices for improving reading ability and/or comprehension for a plurality of subjects are provided. The multi-user portable electronic devices may include a pitch shifter circuit configured to generate frequency altered auditory speech feedback (FAF) signals corresponding to respective auditory speech signals received from respective active microphones, and to transmit the respective FAF signals to the plurality of subjects while one or more of the plurality of subjects are respectively reading aloud, to improve the plurality of subjects' reading ability and/or comprehension. The multi-user portable electronic devices may also include a switch configured to activate the microphones selectively, serially. Related methods and systems are also described.

Abstract: Multi-user portable electronic devices for improving reading ability and/or comprehension for a plurality of subjects are provided. The multi-user portable electronic devices may include a pitch shifter circuit configured to generate frequency altered auditory speech feedback (FAF) signals corresponding to respective auditory speech signals received from respective active microphones, and to transmit the respective FAF signals to the plurality of subjects while one or more of the plurality of subjects are respectively reading aloud, to improve the plurality of subjects' reading ability and/or comprehension. The multi-user portable electronic devices may also include a switch configured to activate the microphones selectively, serially. Related methods and systems are also described.

Abstract: Embodiments of the present invention relate to the detection of synchronization marks in data storage and retrieval. According to one embodiment, synchronization marks are detected from the output of a matched filter, upstream of the Viterbi detector. This approach avoids the delay associated with the latency of the Viterbi output, thereby allowing time to align parity framing and to properly start the time-varying trellis. Certain embodiments disclose 34- and 20-bit primary synchronization marks located at the beginning of a data region. Other embodiments disclose 16-, 20-, and 24-bit embedded synchronization marks located within a data region.

Abstract: Embodiments of the present invention relate to the detection of synchronization marks in data storage and retrieval. To detect a synchronization mark, embodiments of the present invention require both pattern matching and proper phase alignment, following a repeating synchronization field. According to one particular embodiment, proper phase alignment following a repeated four bit synchronization field, is utilized in conjunction with pattern matching, to identify a synchronization mark. By allowing a synchronization mark to be identified only with proper phase alignment at the earliest possible occurrence of the synchronization mark, accuracy of synchronization mark detection may be improved.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

Abstract: The instant invention describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulating angiotensin activity to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system. The disclosure includes compositions and methods based on use of a 4-acylaminopyridine derivative in combination with one or more other neurogenic agents. One 4-acylaminopyridine derivative is MKC-231.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a PDE agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulating angiotensin activity to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a GABA agent or GABA analog, in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulation angiotensin activity to stimulate or activate the formation of new nerve cells.

Abstract: The disclosure provides compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure provides compositions and methods based on the use of D-cycloserine in combination with the neurogenic agent, which synergistically stimulates or activates the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use nootropic agents, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more neurogenic agents, to stimulate or increase a neurogenic response and/or to treat a nervous system disease or disorder.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, in combination with one or more other neurogenic agents, or anti-astrogenic agent, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.